Compare USA Rare Earth Inc. Class A Common Stock (USAR) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
USA Rare Earth Inc. Class A Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? USA Rare Earth Inc. Class A Common Stock trades at $10.2 (market cap $4.23B), while Health Care Select Sector SPDR Fund trades at $174.7 (market cap $44.49B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 10.5× USA Rare Earth Inc. Class A Common Stock's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold USA Rare Earth Inc. Class A Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| USAR | XLV | |
|---|---|---|
Market Cap | $4.23B | $44.49B |
Volume | 13,677,660 | 8,745,019 |
Sector | Basic Materials | — |
52-Week High | $33.68 | $175.68 |
52-Week Low | $10.32 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $2.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
XLV trades at $169.66, down 1.35% on the day, while maintaining a bullish technical outlook with strong moving average support. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 60 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and its competitive positioning against peer healthcare ETFs.
The ETF offers defensive growth exposure with healthcare sector stability, though elevated RSI levels suggest near-term consolidation. Political volatility and pharmaceutical trial failures present sector-specific risks, while XLV's technical strength and institutional interest support continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
